Horizon Therapeutics (HZNP) Misses Q1 EPS by 13c, Offers FY Guidance
- Tech megacaps, chipmakers set to drag Nasdaq lower at open
- EV Company Polestar To Go Public Via $20 Billion SPAC Deal
- Amazon (AMZN) Price Target Lowered at Morgan Stanley Amid Rising Logistics Workforce Costs, Analyst Expects Stock to be Range Bound in Near Term
- Brent oil nears $80 a barrel on tight supply
- Some Apple (AAPL) and Tesla (TSLA) Suppliers Suspend Production in China For a Few Days
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Horizon Therapeutics (NASDAQ: HZNP) reported Q1 EPS of $0.03, $0.13 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $342.4 million versus the consensus estimate of $382.14 million.
Horizon Therapeutics sees FY2021 revenue of $2.75-2.85 billion, versus the consensus of $2.81 billion.
- The Company now expects full‐year 2021 net sales to range between $2.75 billion and $2.85 billion, updated from the previous range of $2.70 billion and $2.80 billion. Full-year 2021 adjusted EBITDA is now expected to range between $1.02 billion and $1.06 billion, updated from the previous guidance of $1.14 billion and $1.18 billion. The updated guidance ranges incorporate Viela, which was acquired on March 15, 2021. The Company continues to expect TEPEZZA full-year 2021 net sales of greater than $1.275 billion and KRYSTEXXA full-year 2021 net sales of greater than $500 million.
For earnings history and earnings-related data on Horizon Therapeutics (HZNP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- S&W Seed (SANW) Tops Q4 EPS by 4c
- Tarena Int'l (TEDU) Reports Q2 Loss of $0.22/sh
- Rite Aid (RAD) Tops Q2 EPS by 1c, Offers Guidance
Create E-mail Alert Related CategoriesEarnings, Guidance
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!